In brief · RUO
- After a heart attack, muscle dies and scar tissue (fibrosis) forms, weakening the pump. Researchers study whether peptides can favorably influence this.
- There are three main targets: growing blood vessels, limiting scarring and protecting mitochondria.
- Thymosin β4 (related to TB-500) showed a signal in a small 2025 infarct study — but the timing of dosing appears crucial, and it makes no new heart-muscle cells.
- Elamipretide gained FDA approval in 2025 for a rare mitochondrial heart disease — but earlier failed in ordinary heart failure.
- Much of this work is preclinical (animal/cell). This article discusses research; Peplife supplies these compounds strictly Research Use Only.
What is this about?
The heart has limited ability to repair itself. In an infarction a coronary artery becomes blocked; the muscle behind it loses its oxygen supply and dies. The body doesn't "repair" that gap with new muscle, but with scar tissue (fibrosis) — stiff material that doesn't pump. The heart becomes stiffer and weaker. Researchers ask whether certain peptides can steer this process. Up front: this is largely basic and preclinical research, and the results are often overstated online.
What is fibrosis? Fibrosis is the buildup of stiff scar tissue. In the heart it replaces functional muscle, making the heart a poorer pump. Much cardiac research is about limiting or "reversing" fibrosis.
Under the hood: three targets
To understand the studies it helps to know where peptides act:
1. Angiogenesis (vessel growth). Damaged tissue needs oxygen. Some peptides stimulate new blood-vessel growth so surviving tissue stays fed.
2. Anti-fibrosis (scar limitation). By inhibiting the cells that make scar tissue (e.g., via the enzyme ROCK1), researchers try to limit damage.
3. Mitochondrial protection. The heart cell is extremely energy-hungry; its mitochondria are vulnerable to oxygen shortage. Peptides that protect mitochondrial structure can limit cell death.
What does this mean? None of these peptides "grows a new heart." They aim to limit existing damage and support repair — a subtler and more realistic goal than the miracle-cure stories online.
Thymosin β4 (related to TB-500)
Thymosin β4 (Tβ4) is an endogenous peptide involved in cell movement and tissue repair. In 2025, a study reported in Cardiovascular Research both mouse experiments and a small study in heart-attack patients (STEMI). The most nuanced finding: patients who within 8 hours were dosed after an angioplasty/stent procedure had smaller infarct areas after 90 days — but across all patients combined the effect was not statistically significant. In other words: if it works at all, it seems to time window determining (PubMed). A second study described how Tβ4 inhibits scar formation, namely via the enzyme ROCK1 (IJMS 2025).
The important correction. A genetic cell-tracing study showed that after a heart attack Tβ4 does not create new beating heart-muscle cells — the cells involved become connective-tissue cells, not muscle (PubMed 2012). The benefits under study therefore work via blood vessels and signalling molecules, not via muscle regeneration. This is exactly the kind of claim that often goes wrong online.
"TB-500" is also a fragment of Thymosin β4; by far most research concerns the full Tβ4 molecule, not the fragment specifically.
Elamipretide (SS-31): the mitochondrial route
Elamipretide stabilizes cardiolipin, a lipid essential to mitochondrial structure. In September 2025 the FDA approved it for Barth syndrome, a rare inherited mitochondrial heart disease — the first therapy targeting such a mechanism (UMDF). Important counterweight: in ordinary heart failure (the PROGRESS-HF phase 2 study) it did not (PubMed). The lesson: promising for a specific, well-understood mechanism, not a cure-all for the heart.
Apelin / ELABELA
Apelin and ELABELA act on the APJ receptor, influencing vessel dilation, pumping strength and fluid balance — a system that becomes dysregulated in heart failure. 2025 reviews describe both the potential and the main hurdle: the natural peptides are broken down very quickly in blood, making them hard to use as a drug (IJMS 2025; Frontiers 2025). A meta-analysis of animal studies suggests early apelin after heart injury may preserve function (PMC).
Humanin and BPC-157
Humanin, a peptide encoded by mitochondrial DNA, reduced age-related heart fibrosis in mice (PMC) and protected the vessel wall (PubMed). BPC-157 is described in animal research as vessel- and heart-protective (review 2022) — but note: there are no human cardiovascular studies; this is heavily overstated online.
Overview: what do we know per peptide?
| Peptide | Researched mechanism | Strongest evidence | Evidence level |
|---|---|---|---|
| Thymosin β4 / TB-500 | angiogenesis, anti-fibrosis (ROCK1) | small STEMI signal, timing-dependent (2025) | preclinical + weak human signal |
| Elamipretide (SS-31) | mitochondrial protection (cardiolipin) | FDA approval Barth syndrome (2025) | clinical (niche disease); failed in general HF |
| Apelin / ELABELA | APJ receptor: dilation, pumping | animal meta-analysis (2024) | preclinical; rapidly degraded |
| Humanin | anti-fibrosis, endothelial protection | mouse studies | preclinical |
| BPC-157 | vessel/tissue protection | animal research | preclinical only |
Nuance & limitations (important)
- Largely preclinical. Except elamipretide (for one rare disease), nearly everything here rests on animal and cell research, which does not automatically translate to humans.
- Timing and context seem decisive. The Tβ4 signal appeared only with very early dosing — a detail often lost in popular summaries.
- No muscle regeneration. The persistent claim that these peptides "rebuild a damaged heart" is contradicted by cell-tracing research.
- Degradation speed. Promising peptides like apelin are so short-lived in the body that they are (still) hard to use therapeutically.
Related research · RUO
- Knowledge base: TB-500 research, SS-31 research and NAD+ and glutathione research (internal compound pillars going deeper on the individual substances).
- RUO research materials: TB-500, BPC-157, humanin (laboratory research only).
Frequently asked questions
Do peptides repair a damaged heart?
Research studies whether they influence processes like vessel growth and scar limitation. Much is preclinical; it is not a proven treatment.
Does Thymosin β4 make new heart-muscle cells?
No — cell-tracing research shows the effect works via vessels and signaling, not new muscle cells.
Why did Tβ4 work only in some patients?
The signal appeared only with dosing within ~8 hours; timing seems crucial.
What is elamipretide approved for?
The rare Barth syndrome (2025); not general heart failure.
Does Peplife supply a CoA?
Yes, independently tested with a CoA per batch.
Disclaimer
This article discusses scientific research and is informational only. The compounds mentioned are supplied by Peplife strictly as Research Use Only (RUO). Nothing here is medical, diagnostic, or dosing advice. Named medicines are cited only to discuss published research.